

## **AMENDMENT**

### **In the Specification:**

**At page 1, line 2, please insert the following paragraphs:**

#### **CROSS-REFERENCE TO RELATED APPLICATIONS**

This application is a national phase application under 35 U.S.C. § 371 of International Application No. PCT/EP2004/006460 filed 16 June 2004, which claims priority to European Application No. 03450148.6 filed 17 June 2003. The entire text of each of the above-referenced disclosures is specifically incorporated herein by reference without disclaimer.

#### **INCORPORATION BY REFERENCE OF SEQUENCE LISTING SUBMITTED ON A COMPACT DISC**

The Sequence Listing is submitted on one compact disc (Copy 1), together with a duplicate thereof (Copy 2), each created on December 19, 2005, and each containing one 264 kb file entitled "SONN085.APP.TXT." The material contained on the compact disc is specifically incorporated herein by reference.

**At page 10, please replace the last paragraph, spanning pages 10-11, with the following substitute paragraph:**

In a preferred embodiment the pharmaceutical composition further comprises an immunostimulatory substance, preferably selected from the group comprising polycationic polymers, especially polycationic peptides, immunostimulatory deoxynucleotides (ODNs), peptides containing at least two LysLeuLys motifs, especially KLKLLLLLK (SEQ ID NO:121), neuroactive compounds, especially human growth hormone, alumn, Freund's complete or incomplete adjuvants or combinations thereof.

**At page 37, please replace the last paragraph, spanning pages 37-38, with the following substitute paragraph:**

Polycationic compounds derived from natural sources include HIV-REV or HIV-TAT (derived cationic peptides, antennapedia peptides, chitosan or other derivatives of chitin) or other peptides derived from these peptides or proteins by biochemical or recombinant

production. Other preferred polycationic compounds are cathelin or related or derived substances from cathelin. For example, mouse cathelin is a peptide, which has the amino acid sequence NH<sub>2</sub>-RLAGLLRKGGEEKIGEKLKKIGOKIKKNFFQKLVPQPE-COOH NH<sub>2</sub>-RLAGLLRKGGEEKIGEKLKKIGOKIKKNFFQKLVPQPE-COOH (SEQ ID NO:122). Related or derived cathelin substances contain the whole or parts of the cathelin sequence with at least 15-20 amino acid residues. Derivations may include the substitution or modification of the natural amino acids by amino acids, which are not among the 20 standard amino acids. Moreover, further cationic residues may be introduced into such cathelin molecules. These cathelin molecules are preferred to be combined with the antigen. These cathelin molecules surprisingly have turned out to be also effective as an adjuvant for an antigen without the addition of further adjuvants. It is therefore possible to use such cathelin molecules as efficient adjuvants in vaccine formulations with or without further immunactivating immunoactivating substances.

**Please delete the Sequence Listing numbered pages 1-25, and replace it with the Sequence Listing submitted concurrently herewith on compact disc.**